Teva Pharmaceutical Industries (TEVA.O) (TEVA.TA) Chief Executive Officer Shlomo Yanai says: * Completed commercial integration of Ratiopharm in 4 months * MS treatment Copaxone "will be with us for many years and will be profitable" * FDA approval for oral MS treatment Laquinimod could be obtained by mid-2012 (Reporting by Tova Cohen)
Source
